Opportunities and Limitations for Biotechnology Innovation in Brazil

by

Luiz A.B. de Castro

DOI: 10.2174/97816080569651130101
eISBN: 978-1-60805-696-5, 2013
ISBN: 978-1-60805-753-5



Indexed in: EBSCO.

Brazil has emerged as a significant financial and industrial power in recent times. Brazil is poised to become a sign...[view complete introduction]
US $
Buy Personal eBook
49
Order Library eBook
196
Order Printed Copy
*64
Order PDF + Printed Copy (Special Offer)
*88

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Biopharmaceuticals from Brazil

- Pp. 29-66 (38)

Luiz A.B. de Castro

Abstract

Biopharmaceuticals are mainly: recombinant proteins, monoclonal antibodies, products derived from nucleic acids and products derived from cells and tissues. The first product was humulin, released 28 years ago. There are 200 biopharmaceuticals approved for use in humans, and all but 2 are proteins. The global market value is close to 100 billion dollars, but there are 2000 products in development process which have not been released yet. As only 0.1% of the products released for human uses are derived from secondary metabolism metabolites, we may clearly notice that even among the 2000 products under development, only a small fraction belongs to the secondary metabolism group. Actually, the biotech pipelines overwhelmed by proteins. The Brazilian Biodiversity (Fig. 1) reserves this space among the biopharmaceuticals to toxins and poisons from reptiles, amphibians and insects, besides various microorganisms and substances from the marine biome. The following analysis, though, describes important adjustments, which are necessary, regarding the laws that regulate access to biodiversity and the patent law.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science